Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3384272 | 0.98 | KDM4E (0.43) | KDM4EHSD17B10TSHRALOX15GAA | |
| Sulfuric Acid SCHEMBL11797700 | 0.98 | KDM4E (0.43) | KDM4EHSD17B10TSHRALOX15GAA | |
| Water SCHEMBL7481158 | 0.86 | — | — | |
| Tetramethylammonium Ion SCHEMBL8829717 | 0.84 | L3MBTL1 (0.42) | KDM4EHSD17B10TSHRALOX15GAA | |
| SCHEMBL474212 | 0.83 | — | — | |
| SCHEMBL3167 | 0.83 | — | — | |
| SCHEMBL8135220 | 0.83 | — | — | |
| Fluoride SCHEMBL7750159 | 0.83 | — | — | |
| Fluoride SCHEMBL11426086 | 0.83 | USP2 (0.46) | KDM4EHSD17B10TSHRALOX15GAA | |
| SCHEMBL28231022 | 0.83 | USP2 (0.46) | KDM4EHSD17B10TSHRALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131196-A1 | Rapamycin Analog | MOUNT TAM THERAPEUTICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| EP-3576736-A1 | RAPAMYCIN ANALOG | Mount Tam Therapeutics, Inc. (US) | 2019-12-11 | — | — | EP | disclosed |
| WO-2018148508-A1 | RAPAMYCIN ANALOG | MOUNT TAM BIOTECHNOLOGIES, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| EP-2797929-B1 | NOVEL RAPAMYCIN ANALOGUE | BUCK INST RES AGING (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9605001-B2 | Production of polyketides and other natural products | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2017-03-28 | — | — | US | disclosed |
| US-9382266-B2 | Rapamycin analogue | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2471797-B1 | 17-DESMETHYLRAPAMYCIN AND ANALOGUES THEREOF, METHODS FOR THEIR PRODUCTION AND THEIR USE AS IMMUNOSUPRESSANTS, ANTICANCER AGENTS, ANTIFUNGAL AGENTS ETC. | BUCK INST FOR RES ON AGING (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20150266896-A1 | PRODUCTION OF POLYKETIDES AND OTHER NATURAL PRODUCTS | BIOTICA TECH LTD (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150210714-A1 | NOVEL RAPAMYCIN ANALOGUE | BUCK INSTITUTE FOR RESEARCH ON AGING | 2015-07-30 | — | — | US | disclosed |
| EP-1521828-B1 | PRODUCTION OF POLYKETIDES | BUCK INST FOR RES ON AGING (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2006095185-A1 | 39-DESMETHOXY DERIVATIVES OF RAPAMYCIN | BIOTICA TECHNOLOGY LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205757-A1 | 39-desmethoxyrapamycin, compositions and methods of use thereof | BIOTICA TECHNOLOGY LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| EP-1655372-A2 | Production of polyketides and other natural products | Biotica Technology Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-20060078980-A1 | Production of polyketides and other natural products | GREGORY MATTHEW A | 2006-04-13 | — | — | US | disclosed |
| WO-2006016167-A2 | 17-DESMETHYLRAPAMYCIN AND ANALOGUES THEREOF, METHODS FOR THEIR RODUCTION AND THEIR USE AS IMMUNOSUPRESSANTS, ANTICANCER AGENTS, ANTIFUNGAL AGENTS, ETC. | BIOTICA TECHNOLOGY LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| US-20050272132-A1 | Production of polyketides and other natural products | BIOTICA TECHNOLOGY LIMITED (GB) | 2005-12-08 | — | — | US | disclosed |
| EP-1589031-A2 | Production of polyketides and other natural products | Biotica Technology Limited (GB) | 2005-10-26 | — | — | EP | disclosed |
| CN-1668741-A | Production of polyketides and other natural products | BIOTICA TECH LTD (GB) | 2005-09-14 | — | — | CN | disclosed |
| EP-1521828-A2 | PRODUCTION OF POLYKETIDES | Biotica Technology Limited (GB) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007709-A2 | PRODUCTION OF POLYKETIDES | BIOTICA TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266896-A1 | PRODUCTION OF POLYKETIDES AND OTHER NATURAL PRODUCTS | FKBP14, FKBP4, FKBP2 | KDM4E 3459/4885HSD17B10 547/4885TSHR 3950/4885 |
| US-20200131196-A1 | Rapamycin Analog | RICTOR, MTOR, RPTOR | KDM4E 1838/4885HSD17B10 2503/4885TSHR 2662/4885 |
| US-20150210714-A1 | NOVEL RAPAMYCIN ANALOGUE | MTOR, RICTOR, MAPKAP1 | KDM4E 2862/4885HSD17B10 1388/4885TSHR 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.